Dr. Risa M. Wolf, M.D.
Pediatric Endocrinology (Pediatric Endocrinology Physician)
200 N Wolfe St Bldg Rm3120
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
MD license D83736 · FL license ME124446 -
Pediatrics Physician
PA license MD441399
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $6,507 in total to this clinician.
| Genzyme Corporation | $6,420 |
|---|---|
| Sanofi-aventis U.S. LLC | $66.82 |
| Insulet Corporation | $19.98 |
| Consulting Fee | $5,946 |
|---|---|
| Travel and Lodging | $309 |
| Food and Beverage | $252 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 19, 2025 | Consulting Fee TZIELD · Endocrine & Metabolic Diseases | $5,946 |
| Genzyme Corporation Jun 19, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Chicago, IL · in-kind | $309 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $101,286 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company · Completed · NCT06362265
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.